Myomo

Myomo operates in medical devices and health care, with a focused offering in powered upper-limb orthoses rather than a broad portfolio of general rehabilitation equipment. Its MyoPro device uses non-invasive sensors to detect residual muscle signals and assist arm and hand movement for people with weakness or partial paralysis. The product ecosystem also includes MyoGames for exercise-based practice, MyoCare post-delivery support, and clinician-facing configuration software. That combination of a fitted wearable device, clinical services, and connected training tools differentiates its approach within assistive rehabilitation. The company serves patients through trained clinical providers and a network of orthotics and prosthetics practices; its 2026 access announcements involving Ottobock clinics and Anthem Blue Cross Blue Shield contracts add distribution and payer dimensions to its market reach. Myomo is publicly traded under the symbol MYO and has raised $55.1 million in structured funding data, including post-IPO equity and debt.

Myomo’s trajectory reflects a shift from early venture financing toward public-market funding and a more developed commercial offering. Its listed funding history begins with a $616,765 venture round in 2009, followed by two Series A rounds in 2012 and 2013 and a $5 million Series B in 2015. The company went public in June 2017, then recorded later post-IPO equity and debt rounds, including $15 million in December 2024 and $12.5 million in November 2025. The 2024 registered direct offering reported separately adds a funding-history discrepancy against the structured round total. Operationally, Myomo reported workforce growth from 100 to 190 employees during 2024, followed by a headcount reduction and limited near-term hiring as of August 2025. Product milestones include the MyoPro 2x launch in April 2025 and the Myomo Mobile App in 2026.